COPD is a leading cause of death worldwide, and was the third top cause of disease-related mortality in the U.S. in 2014.

Current COPD treatments are symptomatic and supportive, but do not address the disease’s underlying causes. Researchers are looking at numerous new concepts in the development of COPD, from the potential role of proteases to the oxidative stress caused by cigarette smoking, infection due to latent viruses. They are also studying known mechanisms that might play a role in COPD development and progression, like mucus hypersecretionprogrammed-cell death (called apoptosis), and the role of blood vessels. They are also looking at treatments of possible relevance to COPD like alveolar regeneration and general disease characteristics in a search for new treatments, like identifying new blood biomarkersgenetics and inflammation.1

This section offers readers more information into this ongoing research work.

Abediterol (LAS100977, AZD5484)

AF219

AZD1236

AZD1981

Benralizumab

BIO11006

CHF5259

CHF5993

Closed Triple combination therapy

Immunotherapy

Mepolizumab

Mometasone – formoterol

Oral beta-alanine

PUR0200

SUN101/ eFlow

TD4208

Tetrahydrobiopterin (Kuvan)

 

COPD News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

1.https://www.nhlbi.nih.gov/health-pro/resources/lung/chronic-obstructive-pulmonary-disease-future-research/workshop-summary